{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:04:27Z","timestamp":1760058267707,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FIS","award":["PI11\/02303"],"award-info":[{"award-number":["PI11\/02303"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>To date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candidates for omalizumab treatment, forced spirometry and blood IgE were measured at entry and at each six-month visit, and free-IgE blood concentrations were measured at month 6. At month 18, the OMADORE protocol was applied. The complete follow-up lasted 30 months. Patients were considered responders if they met at least one of the following criteria: increase in forced expiratory volume in one second (FEV1) at the follow-up visit compared to baseline; reduction in corticosteroid dose at the last visit compared to baseline; reduction in omalizumab dose at the follow-up visit; a positive score on the composite index combining all three criteria. The biomarker used to predict treatment response was the free IgE value and the percentage of free IgE to total IgE measured at visit 1, after six months of omalizumab treatment. The percentage of responders varied according to the parameter used (FEV1, omalizumab, corticosteroid dose, and the composite index; 45.2%, 64.5%, 48.4%, and 77.4%, respectively). IgE blockade was around 97% both for the group as a whole and for the subgroups. There were no differences in free IgE values nor in the ratio of free IgE to total IgE between responders and non-responders. These results confirm that there is a group of patients who may benefit from the reduction\/withdrawal of omalizumab. Determination of free IgE six months after initiation of omalizumab treatment does not discriminate between responders and non-responders.<\/jats:p>","DOI":"10.3390\/ijms26072852","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T10:10:08Z","timestamp":1742551808000},"page":"2852","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-773X","authenticated-orcid":false,"given":"Christian","family":"Domingo","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08208 Sabadell, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1913-6547","authenticated-orcid":false,"given":"Daniel-Ross","family":"Monserrate","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08208 Sabadell, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8055-0103","authenticated-orcid":false,"given":"Markus","family":"Ollert","sequence":"additional","affiliation":[{"name":"Clinical Research Division of Molecular and Clinical Allergotoxicology, Department of Dermatology and Allergy, Technische Universit\u00e4t M\u00fcnchen, 80802 M\u00fcnich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-414X","authenticated-orcid":false,"given":"Xavier","family":"Pomares","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08208 Sabadell, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8133-3274","authenticated-orcid":false,"given":"Carles","family":"Forn\u00e9","sequence":"additional","affiliation":[{"name":"Heorfy Consulting, 25007 Lleida, Spain"},{"name":"Department of Basic Medical Sciences, University of Lleida, 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-2211","authenticated-orcid":false,"given":"Jorge del","family":"del Estal","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08208 Sabadell, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-3061","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Amengual","sequence":"additional","affiliation":[{"name":"Laboratory Department, Immunology Unit, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08208 Sabadell, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26368","DOI":"10.1016\/S0021-9258(18)47203-1","article-title":"The Binding Site on Human Immunoglobulin E for Its High Affinity Receptor","volume":"269","author":"Presta","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-014-0203-y","article-title":"Omalizumab for Severe Asthma: Efficacy beyond the Atopic Patient?","volume":"74","author":"Domingo","year":"2014","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40265-017-0810-5","article-title":"Overlapping Effects of New Monoclonal Antibodies for Severe Asthma","volume":"77","author":"Domingo","year":"2017","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pharmthera.2006.07.003","article-title":"Immunoglobulin E: Role in Asthma and Allergic Disease: Lessons from the Clinic","volume":"113","author":"Owen","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1398-9995.2006.01180.x","article-title":"Omalizumab Decreased IgE-release and Induced Changes in Cellular Immunity in Patients with Allergic Asthma","volume":"61","author":"Hanf","year":"2006","journal-title":"Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000070434","article-title":"Immunological and Clinical Changes in Allergic Asthmatics Following Treatment with Omalizumab","volume":"131","author":"Noga","year":"2003","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of Treatment with Anti-Immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma","volume":"170","author":"Wilson","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ab.2010.12.013","article-title":"Quantitation of Serum IgE by Using Chimeras of Human IgE Receptor and Avian Immunoglobulin Domains","volume":"412","author":"Braren","year":"2011","journal-title":"Anal. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/0394632016670920","article-title":"Omalizumab: A Useful Tool for Inducing Tolerance to Bee Venom Immunotherapy","volume":"29","author":"Ricciardi","year":"2016","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1067\/mai.2001.115039","article-title":"Expression of the High-Affinity IgE Receptor on Peripheral Blood Dendritic Cells: Differential Binding of IgE in Atopic Asthma","volume":"107","author":"Holloway","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"21","author":"Colice","year":"2020","journal-title":"Respir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jlb.66.2.201","article-title":"Corticosteroids Inhibit the Production of Inflammatory Mediators in Immature Monocyte-Derived DC and Induce the Development of Tolerogenic DC3","volume":"66","author":"Vieira","year":"1999","journal-title":"J. Leukoc. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2567.1997.00321.x","article-title":"Steroids Inhibit Uptake and\/or Processing but Not Presentation of Antigen by Airway Dendritic Cells","volume":"91","author":"Holt","year":"1997","journal-title":"Immunology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/(SICI)1521-4141(200004)30:4<1233::AID-IMMU1233>3.0.CO;2-F","article-title":"Differential Effects of Corticosteroids during Different Stages of Dendritic Cell Maturation","volume":"30","author":"Matyszak","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Domingo, C., Monserrate, D.R., Sogo, A., and Mirapeix, R.M. (2024). The Incredible Adventure of Omalizumab. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25053056"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rojo-Tolosa, S., Gonz\u00e1lez-Guti\u00e9rrez, M.V., S\u00e1nchez-Mart\u00ednez, J.A., Jim\u00e9nez-G\u00e1lvez, G., Pineda-Lancheros, L.E., G\u00e1lvez-Navas, J.M., Jim\u00e9nez-Morales, A., P\u00e9rez-Ram\u00edrez, C., and Morales-Garc\u00eda, C. (2023). Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020523"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/eji.1830240934","article-title":"Inhibition of Human IgE Synthesis by Anti-IgE Antibodies Requires Divalent Recognition","volume":"24","author":"Miescher","year":"1994","journal-title":"Eur. J. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/2852\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:57:57Z","timestamp":1760029077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/2852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26072852"],"URL":"https:\/\/doi.org\/10.3390\/ijms26072852","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}